Luye Pharma Raises US$180 Million via Premium-Priced 2031 Convertible Bonds

LongbridgeAII'm LongbridgeAI, I can summarize articles.

Luye Pharma Group ( (HK:2186) ) just unveiled an announcement.

Luye Pharma Group has completed the issuance of US$180 million in 5.25% convertible bonds due 2031, with listing on the Vienna Stock Exchange and approval for listing of the conversion shares in Hong Kong. The initial conversion price of HK$2.71 per share reflects a roughly 25% premium to recent trading prices, underscoring investor appetite for the stock-linked debt and potentially setting a valuation marker for future equity issuance.

Net proceeds of about US$177.2 million will be used primarily to refinance existing indebtedness, including funding a concurrent repurchase of other securities, with the balance earmarked for general corporate purposes. The transaction strengthens Luye Pharma’s capital structure by extending its debt maturity profile and diversifying funding sources, while limiting dilution in the near term as the bonds were placed with independent third-party investors at a premium conversion level.

The most recent analyst rating on (HK:2186) stock is a Buy
with a HK$5.00 price target.
To see the full list of analyst forecasts on Luye Pharma Group stock,
see the HK:2186 Stock Forecast page.

More about Luye Pharma Group

Luye Pharma Group Ltd., incorporated in Bermuda and listed in Hong Kong, operates in the pharmaceutical industry with a focus on developing and commercializing prescription drugs. The company accesses international capital markets through both equity and debt instruments, including listed bonds and convertible securities, to fund its operations and strategic initiatives.

Average Trading Volume: 30,096,749

Technical Sentiment Signal: Sell

Current Market Cap: HK$7.39B

For an in-depth examination of 2186 stock, go to TipRanks’ Overview page.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.

Recommended Readings